Treatment-Resistant Depression: A Psychiatry Perspective on Pathophysiological Mechanisms, Biomarkers, and Novel Therapeutic Frontiers

Treatment-resistant depression (TRD) affects many people with major depressive disorder who do not get better after adequate medication. TRD is a varied condition driven by complex interactions among brain, immune, and social factors. Better understanding of its causes—including brain inflammation, problems with how brain cells communicate, and hormone imbalances—has helped identify possible markers for diagnosis and new treatments. This perspective discusses these underlying mechanisms, highlights promising biomarkers for diagnosis and treatment planning, and covers emerging therapies such as fast-acting antidepressants, brain stimulation, and psychedelic-assisted therapy. Combining these advances into medical care may allow more personalized and effective management of TRD.

Study at a glance

Abstract

Treatment-resistant depression (TRD) represents a major clinical and public health challenge, affecting a substantial proportion of patients with major depressive disorder who fail to achieve remission despite adequate pharmacotherapy. Emerging evidence suggests that TRD is a heterogeneous condition driven by complex interactions among neurobiological, inflammatory, and psychosocial factors. Advances in understanding pathophysiological mechanisms—including neuroinflammation, synaptic dysfunction, and neuroendocrine dysregulation—have facilitated the identification of potential biomarkers and the development of novel therapeutic strategies. This perspective explores current insights into the mechanisms underlying TRD, highlights promising biomarkers for diagnosis and treatment stratification, and discusses emerging therapeutic frontiers such as rapid-acting antidepressants, neuromodulation, and psychedelic-assisted therapy. Integrating these advances into clinical practice may enable a more personalized and effective approach to managing TRD.